A supplement may tame the Gut-Wrenching side effects of h. pylori therapy
NCT ID NCT07729293
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial tests whether a dietary supplement called Pylori Duo, which contains probiotics and licorice extract, can reduce gastrointestinal side effects from standard H. pylori treatment and help prevent the infection from coming back. About 140 adults with confirmed H. pylori infection will receive standard quadruple therapy plus either Pylori Duo or a placebo for 10 days, followed by the supplement or placebo alone for three months. Researchers will track side effects, eradication rates, and recurrence over a year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a dietary supplement containing Lactobacillus rhamnosus and dried licorice extract, called Pylori Duo
- What this could lead to
- If it works, this could point toward a way to make standard H. pylori treatment easier to tolerate and lower the chance of the infection returning.
- What could go wrong
- This is a single-center trial with 140 participants, so results may not apply to everyone. The supplement is tested alongside standard therapy, so its added benefit may be small.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 140 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 to 70 years. * Confirmed Helicobacter pylori infection prior to treatment, as determined by a positive 13C-urea breath test (13C-UBT) and gastric biopsy. * No previous H. pylori eradication therapy. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Significant underlying conditions that, in the opinion of the treating physician, would preclude participation in the study, including hepatic insufficiency (aspartate aminotransferase or alanine aminotransferase \>3 times the upper limit of normal), renal insufficiency (creatinine ≥2.0 mg/dL or glomerular filtration rate \<50 mL/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%, thyroid disease, pulmonary disease, or any other serious medical condition. * Pregnancy, breastfeeding, or unwillingness to use contraception during the study. * Active gastrointestinal bleeding. * History of upper gastrointestinal tract surgery. * History of allergic reactions to medications included in the treatment regimen. * Use of bismuth-containing agents, antibiotics, proton pump inhibitors, or other relevant medications within 4 weeks prior to treatment. * Behaviors that may increase the risk of illness, including excessive alcohol consumption or substance abuse. * Negative repeat urea breath test prior to treatment initiation. * Unwillingness or inability to provide informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dyspepsia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
GALA Laboratories
Don Benito, Badajoz, 06400, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heartburn drug under the microscope: registry tracks thousands of pregnancies
- Can probiotics make h. pylori antibiotics easier on the gut?
- Can a common seed oil boost stomach infection treatment?
- Ear zaps and stomach maps: a new way to read a misbehaving gut
- Can a website teach patients to tame gut pain and skip needless hospital tests?
- Two antibiotic cocktails face off to wipe out stomach bacteria